International Journal of Research in Medical Sciences

Gaikwad KB et al. Int J Res Med Sci. 2026 Nov;14(11):5376-5381

www.msjonline.org

pISSN 2320-6071 | eISSN 2320-6012

Therapeutic outcomes of virechana karma in dyslipidaemia: a case series

Kirti B. Gaikwad*, Meera K. Bhojani


Department of Kriya Sharir, All India Institute of Ayurveda, New Delhi, India

Received: 07 September 2026

Accepted: 12 October 2026

*Correspondence:

Dr. Kirti B. Gaikwad,

E-mail: dr.kirti.aiia399@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Dyslipidaemia is a major global health concern associated with cardiovascular disease, with prevalence ranging from 20% to over 80% depending on region, age, sex, and diagnostic criteria. It is strongly linked to sedentary lifestyle and unhealthy dietary habits. In Ayurveda, dyslipidaemia can be correlated with Medoroga characterized by abnormal accumulation of Medo Dhatu due to impaired Dhatvagni, predominantly involving Kapha and Pitta Dosha. The objective is to evaluate the therapeutic outcome of classical Virechana Karma on lipid profile parameters in patients with dyslipidaemia. Five clinically diagnosed cases aged 18–40 years with disease chronicity of approximately three years were selected after obtaining written informed consent. Classical Virechana Karma was administered followed by Samsarjana Krama. Serum lipid profile parameters were assessed before intervention and after completion of therapy. Post-therapy follow-up of six months included dietary regulation and lifestyle modification. Post-intervention assessment showed reduction in total cholesterol, triglycerides, LDL, and VLDL levels across all cases, with a modest increase in HDL. Intra-individual comparison demonstrated consistent improvement in lipid profile parameters following Virechana Karma. Associated clinical symptoms such as heaviness and lethargy showed reduction. Incidental borderline glycaemic parameters, including HbA1c, improved in select cases, and no adverse events were reported. This case series indicates an association between classical Virechana Karma and improvement in serum lipid profile parameters in dyslipidaemia; however, findings are limited by small sample size and lack of a control group, warranting further controlled studies.

Keywords: Dyslipidaemia, Virechana karma, Medoroga, Shodhana therapy, Case series, Ayurveda

INTRODUCTION

Dyslipidaemia (ICD-10: E78) is a metabolic disorder characterized by abnormal levels of serum lipids and is a major risk factor for cardiovascular disease, the leading cause of mortality worldwide. The global prevalence of dyslipidaemia varies widely, ranging from 20% to over 80%, depending on age, sex, ethnicity, and diagnostic criteria.1,2 Clinically, dyslipidaemia is often asymptomatic but may present with nonspecific features such as lethargy, heaviness, reduced exercise tolerance, and weight gain, leading to underdiagnosis unless biochemical screening is performed. Biochemically, it is characterized by elevated total cholesterol, low-density lipoprotein, very low-density lipoprotein, and triglycerides, along with reduced high-density lipoprotein levels. Conventional management primarily involves pharmacological agents such as HMG-CoA reductase inhibitors and PPAR-α agonists; however, long-term therapy has been associated with adverse effects including hepatotoxicity and increased risk of type-2 diabetes mellitus.3

In Ayurveda, dyslipidaemia can be correlated with Medoroga, classified under Santarpanottha Vyadhi, resulting from over-nutrition and impaired metabolic processing. The pathogenesis is attributed to derangement of Jatharagni and Dhatvagni, leading to defective metabolism and abnormal accumulation of Meda Dhatu. Classical Ayurvedic texts advocate Aptarpana and Langhana Chikitsa for Santarpanottha Vyadhi, with Virechana Karma being a principal Shodhana therapy indicated for elimination of morbid Pitta and Kapha and restoration of metabolic equilibrium. In this context, the present case series evaluates the therapeutic outcome of classical Virechana Karma using contemporary biochemical parameters, thereby assessing its clinical relevance in the management of dyslipidaemia.

CASE SERIES

This case series included patients presenting to a Panchakarma outpatient setting who were identified with dyslipidaemia either incidentally during routine health screening or with a known history of the condition. Patients primarily reported nonspecific complaints such as increased body mass index, fatigue, and dizziness. Initial evaluation comprised detailed clinical history, physical examination, and laboratory investigations. Demographic variables including age, gender, occupation, and duration of illness were recorded for all patients.

Five patients aged between 18 and 40 years, with a disease duration of approximately three years, were included in the study after obtaining written informed consent. Patients with major systemic illnesses, including hypertension, chronic kidney disease, or any acute medical or surgical condition, were excluded. All selected patients fulfilled the criteria for Shodhana Arahata.

Pre- and post-intervention assessment was carried out using serum lipid profile parameters, including total cholesterol, triglycerides, low-density lipoprotein, very low-density lipoprotein, and high-density lipoprotein. Classical Virechana Karma was administered following Deepana, Pachana, Abhyantara Snehapana, Abhyanga, and Swedana, and was completed with Samsarjana Krama. Patients were followed up for six months with dietary regulation and lifestyle modification. Demographic and clinical details of all cases are summarized in Table 1.

Table 1: Baseline demographic and clinical characteristics of patients.
Table reproduced from source PDF page 2

Case 1

A 28-year-old male patient presented with a known history of dyslipidaemia for the past three years. He reported complaints of increased body mass index, persistent fatigue, reduced appetite, and indigestion. The patient had been receiving conventional medical management with HMG-CoA reductase inhibitors for the previous one year; however, no significant improvement was observed. Laboratory investigations revealed elevated total cholesterol and triglyceride levels, while other lipid parameters were within normal limits.

Case 2

A 35-year-old female patient presented with complaints of fatigue and overweight. Dyslipidaemia was detected incidentally during a routine health check-up three years ago. There was no prior history of medication for dyslipidaemia. Laboratory evaluation showed elevated total cholesterol and triglyceride levels, with other lipid parameters within normal range. Thyroid function testing revealed raised thyroid-stimulating hormone levels, and glycated hemoglobin (HbA1c) was also found to be elevated.

Case 3

A 27-year-old female patient presented with a diagnosed case of dyslipidaemia for 3 years, along with complaints of increased body mass index, fatigue, indigestion, and increased abdominal adiposity. The condition had been detected approximately three years prior to presentation, and the patient had not received any medical treatment for the same. Laboratory investigations demonstrated elevated total cholesterol, triglycerides, low-density lipoprotein, and very low-density lipoprotein levels, while other lipid parameters were within normal limits. Thyroid function testing showed elevated thyroid-stimulating hormone levels, and HbA1c was also raised.

Case 4

A 28-year-old female patient presented with diagnosed dyslipidaemia and overweight for three years, identified incidentally during a routine health screening. The patient did not report any prior medical treatment for dyslipidaemia. Laboratory investigations revealed elevated total cholesterol, triglycerides, low-density lipoprotein, and very low-density lipoprotein levels, while remaining lipid parameters were within normal limits.

Case 5

A 28-year-old female patient presented with a known history of dyslipidaemia for the past three years, associated with increased body mass index, fatigue, anorexia, and indigestion. The patient had attempted dietary modification and regular exercise for one month without pharmacological intervention; however, no significant improvement was noted. Laboratory findings showed elevated total cholesterol, triglycerides, and low-density lipoprotein levels, with other lipid parameters within normal limits.

Treatment plan

After observing of all clinical condition and laboratory investigation following treatment were planned as maintained in Table 2.

Table 2: Virechana Karma protocol followed in all patients.
Table reproduced from source PDF page 3

Following completion of Virechana Karma and Samsarjana Krama, all patients were administered a uniform Shodhanottara Shamana regimen aimed at sustaining metabolic correction and preventing recurrence. The details of the post-Virechana Shamana therapy are summarized in Table 3.

Table 3: Post-virechana shamana Chikitsa protocol followed in all patients.
Table reproduced from source PDF page 3

During Phase III, patients were advised to strictly adhere to Pathya Palana with emphasis on Laghu, Ushna and Sukham Paka Ahara to support Agni and prevent Meda accumulation. Intake of Guru, Snigdha, Ati-Madhura, and Abhishyandi Ahara, as well as consumption of food in the absence of hunger, was avoided. Regular Vyayama appropriate to individual capacity was encouraged, while Divaswapa, Atibhojana, and sedentary lifestyle practices were strictly discouraged throughout the follow-up period.

Baseline and post-intervention values of serum lipid profile and glycaemic parameters for individual patients are presented in Table 4 to illustrate case-wise changes following Virechana Karma. Statistical comparison of pre- and post-treatment serum lipid profile and glycaemic parameters was performed using the Wilcoxon signed-rank test and is presented in Table 5.

All five patients completed Virechana Karma, post-procedural Samsarjana Krama, and Shodhanottara Shamana therapy without any adverse events. Pre–post comparison demonstrated a statistically significant reduction in total cholesterol, triglycerides, LDL, and VLDL levels following intervention (p<0.05). HbA1c levels also showed significant improvement, while HDL cholesterol demonstrated a non-significant change.

During follow-up at 1, 3, and 6 months, the improvements observed in serum lipid profile and glycaemic parameters were maintained in the majority of patients, with no rebound increase noted. Associated clinical symptoms showed parallel and sustained improvement throughout follow-up with adherence to Pathya Palana and lifestyle modification, and no delayed adverse events were reported.

Table 4: Case-wise changes in lipid profile and glycemic parameters (Pre–Post).
Table reproduced from source PDF page 4
Table 5: Statistical summary of pre–post changes.
Table reproduced from source PDF page 4

DISCUSSION

Dyslipidaemia is a metabolic disorder characterized by quantitative and qualitative abnormalities in serum lipoproteins, including elevated total cholesterol, triglycerides, LDL, VLDL, and/or reduced HDL, which collectively increase the risk of atherosclerosis and cardiovascular disease. Clinically, dyslipidaemia is often asymptomatic and remains undetected until identified through biochemical screening. The absence of specific symptoms can be attributed to the slow and progressive nature of lipid accumulation and metabolic imbalance; wherein structural and functional disturbances develop at a subclinical level before manifesting as overt cardiovascular pathology.4

In Ayurveda, dyslipidaemia can be correlated with Medoroga, classified under Santarpanottha Vyadhi, where excessive and improper nutrition, sedentary lifestyle, and impaired metabolic processing lead to pathological accumulation of Meda Dhatu.5 The underlying pathogenesis involves dysfunction of Jatharagni and Dhatvagni, resulting in incomplete transformation of nutrients and excessive deposition of unprocessed metabolic by-products. This derangement predominantly involves Kapha and Pitta Dosha, leading to Srotorodha and disturbed lipid metabolism. Due to the predominance of Manda and Snigdha qualities, the disease often lacks prominent pain or inflammatory symptoms in early stages, explaining the paucity of specific clinical manifestations.

Considering the above Samprapti, Virechana Karma was selected as the principal intervention in all cases. Virechana is the prime Shodhana therapy indicated for elimination of morbid Pitta and associated Kapha, particularly in disorders arising from Santarpana and Medo Dushti.6 By expelling accumulated Dosha from their primary site and clearing obstructed Strotas, Virechana helps restore the functional integrity of Agni at both digestive and tissue levels. These classical observations are corroborated by contemporary clinical evidence: a standard controlled clinical trial demonstrated a highly significant reduction in serum lipid parameters following Virechana Karma in patients with dyslipidemia (Medoroga), and a case report similarly documented normalization of lipid profile and metabolic parameters after Virechana Karma in Santarpanajanya Vyadhi with metabolic derangement.7,8

The significant reduction observed in total cholesterol, triglycerides, LDL, and VLDL following intervention in the present series is therefore consistent with this growing body of evidence, and suggests effective correction of the underlying metabolic dysfunction through Shodhana.

From a probable mechanistic perspective, Virechana Karma may influence lipid metabolism by enhancing hepatic processing of lipids, improving bile secretion, and facilitating clearance of circulating lipoproteins. The improvement in triglyceride and VLDL levels observed in most patients indicates effective regulation of lipid transport and storage pathways. Additionally, reduction in HbA1c in patients with borderline baseline values suggests a broader metabolic regulatory role of Virechana, supporting classical descriptions of its Medohara and Agni Deepana actions.9

Following Shodhana, Shodhanottara Shamana Chikitsa was administered to consolidate the metabolic correction achieved through Virechana and to prevent recurrence of Meda Dushti. Varunadi Kwatha is classically indicated in disorders involving Medovaha Srotas and Kapha predominance. Its constituents possess Tikta–Kashaya Rasa, Laghu–Ruksha Guna, Ushna Virya, and Katu Vipaka, which collectively exert Lekhana and Srotoshodhana actions. Through its Mutrala and Medohara properties, Varunadi Kwatha facilitates mobilization and elimination of excess Meda and Kapha-associated metabolic waste, thereby aiding in clearance of Srotorodha and normalization of lipid transport pathways.10 This is corroborated by experimental evidence demonstrating significant antihyperlipidemic activity of Crataeva nurvala (Varuna) bark extracts, with marked reduction in total cholesterol, triglycerides, and LDL in diet-induced hyperlipidemic models, supporting its classical Medohara indication within Varunadi Kwatha.11

Aarogyavardhini Vati plays a pivotal role in restoring Agni and hepatic metabolic functions. With predominant Tikta–Katu Rasa, Ushna Virya, and Katu Vipaka, it acts as a potent Deepana–Pachana formulation, correcting Dhatvagni Mandya and improving transformation of nutrients at the tissue level. Its traditional indication in disorders of Yakrit and Meda suggests a probable role in regulating lipid synthesis and metabolism, thereby contributing to sustained reduction in atherogenic lipid fractions following Shodhana.12 This is supported by an experimental study in which Aarogyavardhini Vati produced a significant, dose-dependent reduction in serum total cholesterol, triglycerides, and LDL with an increase in HDL in hyperlipidemic rats, an effect comparable to fenofibrate, lending pharmacological plausibility to its hypolipidemic action.13

Gokshura Churna, owing to its Madhura Rasa, Sheeta Virya, and Madhura Vipaka, primarily supports Mutravaha Srotas while exerting a balancing effect on Kapha without aggravating Pitta. Its Mutrala and Anulomana properties assist in elimination of excess metabolic by-products and fluid retention associated with Meda Vriddhi, thereby supporting systemic metabolic equilibrium.14 This is in agreement with a randomized placebo-controlled trial in which Tribulus terrestris (Gokshura) supplementation produced a significant reduction in total cholesterol and LDL, lending clinical support to its use in this protocol.14 Musta Churna, characterized by Tikta–Kashaya Rasa, Laghu–Ruksha Guna, and Ushna Virya, acts as a potent Pachana and Kapha-Medohara drug. By correcting Ama and improving digestive efficiency, Musta helps prevent re-accumulation of improperly processed lipids at the level of Meda Dhatu.15 This classical Medohara property is supported by an experimental study reporting significant lipid-lowering activity of alcoholic extract of Cyperus rotundus (Musta) rhizome in hyperlipidaemic rats.16

Collectively, these formulations act synergistically to maintain Agni, promote Lekhana of excess Meda, ensure Srotoshodhana, and stabilize the metabolic correction achieved through Virechana Karma. This integrative Shodhana–Shamana approach facilitates effective Samprapti-bhanga in Medoroga by addressing both root metabolic dysfunction and its downstream manifestations. The sustained improvement during follow-up without rebound elevation of lipid parameters highlights the synergistic role of Shodhana, Shamana, and Pathya Palana in achieving durable therapeutic outcomes.

Although HDL levels did not show statistically significant improvement, stabilization of HDL alongside marked reduction in atherogenic lipid fractions may still be considered clinically beneficial. The findings of this case series, while limited by small sample size and absence of a control group, provide preliminary evidence supporting the role of Virechana Karma as a safe and effective therapeutic modality in dyslipidaemia. Larger controlled clinical trials with longer follow-up are warranted to further validate these observations.

CONCLUSION

This case series suggests that classical Virechana Karma followed by appropriate Shodhanottara Shamana Chikitsa is associated with significant improvement in atherogenic lipid parameters in patients with dyslipidaemia. The sustained metabolic benefits observed during follow-up highlight the role of Shodhana in correcting underlying Meda Dushti and Agni imbalance when supported by Pathya Palana. However, larger controlled clinical studies are required to confirm these findings and establish broader clinical applicability.

Funding: No funding sources

Conflict of interest: None declared

Ethical approval: Not required

REFERENCES

  1. 1. Pirillo A, Casula M, Olmastroni E, Norata GD, Catapano AL. Global epidemiology of dyslipidaemias. Nat Rev Cardiol. 2021;18(10):689-700.
  2. 2. Mohamed-Yassin MS, Baharudin N, Abdul-Razak S, Ramli AS, Lai NM. Global prevalence of dyslipidaemia in adult populations: a systematic review protocol. BMJ Open. 2021;11(12):e049662.
  3. 3. Ramkumar S, Raghunath A, Raghunath S. Statin therapy: review of safety and potential side effects. Acta Cardiol Sin. 2016;32(6):631-9.
  4. 4. Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868-74.
  5. 5. Acharya YT, editor. Charaka Samhita of Agnivesha with Ayurveda Dipika commentary of Chakrapanidatta. Reprint ed. Varanasi: Chaukhamba Sanskrit Samsthan; 2017. Sutrasthana, chapter 23.
  6. 6. Acharya YT, editor. Sushruta Samhita of Sushruta with Nibandha Sangraha commentary of Dalhana. Reprint ed. Varanasi: Chaukhamba Sanskrit Samsthan; 2018. Chikitsasthana, Virechana Adhyaya.
  7. 7. Pooja BA, Bhatted SK. A standard controlled clinical study on Virechana Karma and Lekhana Basti in the management of dyslipidemia (Medoroga). Ayu. 2016;37(1):32-7.
  8. 8. Agarwal S, Srivastava A, Sharma KK, Anand N. A case study on role of Virechana Karma as a conservative management in metabolic syndrome (Santarpana Janya Vyadhi). J Ayurveda Integr Med Sci. 2025;10(2):373-7.
  9. 9. Murthy KRS, translator. Ashtanga Hridaya of Vagbhata. Sutrasthana, Shodhana Phala Adhyaya. Reprint ed. Varanasi: Chaukhamba Krishnadas Academy; 2016.
  10. 10. Bhavamishra. Bhavaprakasha Nighantu. Medohara Varga and Guduchyadi Varga. Reprint ed. Varanasi: Chaukhamba Bharati Academy; 2015.
  11. 11. Sikarwar MS, Patil MB. Anti-hyperlipidemic activity of Crataeva nurvala Buch-Hum ethanolic extract fractions. Int Med J Sifa Univ. 2015;2(1):31-6.
  12. 12. Shastri AD, editor. Bhaishajya Ratnavali of Govind Das. Reprint ed. Varanasi: Chaukhamba Sanskrit Bhawan; 2016. Medoroga Chikitsa Prakarana.
  13. 13. Kumar G, Srivastava A, Sharma SK, Gupta YK. The hypolipidemic activity of Ayurvedic medicine, Arogyavardhini vati in Triton WR-1339-induced hyperlipidemic rats: a comparison with fenofibrate. J Ayurveda Integr Med. 2013;4(3):165-70.
  14. 14. Samani NB, Jokar A, Soveid M, Heydari M, Mosavat SH. Efficacy of the hydroalcoholic extract of Tribulus terrestris on the serum glucose and lipid profile of women with diabetes mellitus: a double-blind randomized placebo-controlled clinical trial. J Evid Based Complementary Altern Med. 2016;21(4):NP91-NP97.
  15. 15. Sharma PV. Dravyaguna Vijnana. Vol. 2. Reprint ed. Varanasi: Chaukhamba Bharati Academy; 2014.
  16. 16. Chandratre RS, Chandarana S, Mengi SA. Lipid lowering activity of alcoholic extract of Cyperus rotundus. Int J Res Pharm Chem. 2011;1(4):1042-5.